Navigation Links
CryoLife Announces First Clinical Use of BioFoam(R)
Date:9/10/2009

ding statements regarding hopes that BioFoam will reduce the time required to achieve hemostasis during liver resection surgery and reduce the number of complications following surgery, potential distribution timing and uses and applications for BioFoam and timing of enrollment in the feasibility phase of the Company's BioFoam IDE submission. These future events may not occur as and when expected, if at all, and, together with the Company's business, are subject to various risks and uncertainties. These risks and uncertainties include that BioFoam may not prove safe or effective for its intended uses, that BioFoam may not achieve hemostasis in liver resections or reduce complications following surgery due to any number of factors that we will not be able to identify until further procedures are performed, that BioFoam may not be useful in other future surgical applications, that the Company may not start feasibility phase enrollment in quarter 4 of 2009 due to any number of factors, including unanticipated delays in obtaining FDA and U.S. Department of Defense approval, and that BioFoam development may not result in a commercial product on the time table anticipated, or at all, due to factors beyond our control, including potential lack of acceptance by the medical community. For additional risks impacting the Company's business, see the Risk Factors section of the Company's Annual Report on Form 10-K for the year ended December 31, 2008 and the Company's subsequent Form 10-Q filings. The Company does not undertake to update its forward-looking statements.

For additional information about the company, visit CryoLife's Web site: http://www.cryolife.com

    Media Contacts:

    D. Ashley Lee
    Executive Vice President, Chief Financial
    Officer and Chief Operating Officer
    Phone:  770-419-3355

    Dana H
'/>"/>
SOURCE CryoLife, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. CryoLifes Second Annual Surgical Congress for the Ross Procedure to Draw More than 130 Cardiovascular Surgeons from Around the World
2. CryoLife Announces Implants of First FDA-Cleared SynerGraft(R) Processed Human Cardiac Patch Material
3. CryoLife Receives FDA 510(k) Clearance for SynerGraft(R) Processed Human Cardiac Patch Material
4. CryoLife Reports Record First Quarter Revenues of $26.7 Million
5. CryoLife Announces Release Date and Teleconference Call Details for 2009 First Quarter Financial Results
6. CryoLife to Present at Sidotis 13th Annual New York Emerging Growth Institutional Forum
7. CryoLife Reports Record Annual Revenues of $105.1 Million for FY 2008
8. CryoLife Announces Release Date and Teleconference Call Details for 2008 Fourth Quarter and Year End Financial Results
9. CryoLife, Inc. Receives Tissue From 100,000th Donor, Marking Industry Milestone
10. CryoLife to Present at 20th Annual Piper Jaffray Health Care Conference
11. CryoLifes Fully Diluted Earnings Per Share Increased 71 Percent to $0.12 in Third quarter of 2008 from $0.07 in Third quarter of 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... 2014 /PRNewswire-iReach/ -- A case study from Intel ... school,s bioengineering department and the Intel® Internet of ... Academic Program, UCSD,s research focuses on exploring the ... Photo - http://photos.prnewswire.com/prnh/20140819/137540 ... of Dr. Todd P. Coleman , Associate ...
(Date:8/20/2014)... 20, 2014 GraphDB™ 6.0 ... including improvements to the enterprise replication cluster, faster ... Lucene, SOLR and Elasticsearch. This release happens to ... performance triplestore – GraphDB™ was formerly known as ... the only mature enterprise resilient RDF triplestore will ...
(Date:8/19/2014)... Aug. 19, 2014 Research and Markets  has announced ... Global Strategic Business Report" report to their offering. ... Culture Supplies in US$ Thousands by the following Product Segments: Media, ... for the US, Canada , Japan ... , and Latin America . Annual estimates and ...
(Date:8/19/2014)... 2014 Research and Markets  has announced the ... Global Strategic Business Report" report to their offering. ... Oxide Fuel Cells (SOFCs) in US$ Thousands. The report provides ... , Europe , Asia-Pacific ... provided for the period 2012 through 2020. Market data and ...
Breaking Biology Technology:Intel and University of San Diego Bioengineering Department Release Case Study on Health Sciences Research 2Ontotext Improves Its RDF Triplestore, GraphDB™ 6.0: Enterprise Resilience, Faster Loading Speeds and Connectors to Full-Text Search Engines Top the List of Enhancements 2Ontotext Improves Its RDF Triplestore, GraphDB™ 6.0: Enterprise Resilience, Faster Loading Speeds and Connectors to Full-Text Search Engines Top the List of Enhancements 3Ontotext Improves Its RDF Triplestore, GraphDB™ 6.0: Enterprise Resilience, Faster Loading Speeds and Connectors to Full-Text Search Engines Top the List of Enhancements 4Global Cell and Tissue Culture Supplies - Strategic Business Report 2014 2Global Solid Oxide Fuel Cells (SOFCs) - Strategic Business Report 2014 2
... their Charleston and Morgantown campuses so students can watch their ... core graduate nursing school courses will be available on the ... nurses and we need more nurse educators to teach the ... at WVU School of Nursing. By using Mediasite Live to ...
... Small Business Development Center, the Madison Development Corp. and ... will also provide on-site assistance for T.E.C. Incubator Center ... Center, Inc. , is a nonprofit corporation providing management ... is a unique partnership between MATC and McAllen Properties, ...
... is a single report writer which allows flexible reporting ... Leader of RedPrairie. It will help us to provide ... RPwriter has the ability to embed graphics and other ... and also provides automatic report generation based on periodic ...
Cached Biology Technology:Sonic Foundry Facilitates Nursing Education 2Sonic Foundry Facilitates Nursing Education 3RedPrairie Employs Report Writer to Expand and Simplify SCE Report Production 2
(Date:8/19/2014)... the world, leprosy and tuberculosis live side-by-side. Worldwide ... per year, with nearly all of them occurring ... vaccine Bacille Calmette-Guerin, or BCG, provides only partial ... more potent vaccine is needed to combat both ... weapon against both diseases., In a study published ...
(Date:8/19/2014)... devised a new implantable tissue scaffold coated with bone ... weeks. When applied to bone injuries or defects, this ... bone that looks and behaves just like the original ... a dramatic improvement over the current standard for treating ... of the patient,s body a painful process that ...
(Date:8/19/2014)... infants born with neonatal abstinence syndrome (NAS) secondary ... time going through withdrawal than others, but the ... and epigenetic (when genes are turned on or ... factors, researchers at Boston University School of Medicine ... first of its kind study to identify some ...
Breaking Biology News(10 mins):New vaccine shows promise as stronger weapon against both tuberculosis and leprosy 2Engineering new bone growth 2Engineering new bone growth 3In-utero methadone, Subutex exposure could alter gene expression, cause severe Neonatal Abstience Syndrome 2
... biofouling affects harbors around the world. It,s the ... on the bottom of boats and other surfaces. ... Kewalo Marine Laboratory have discovered a biological trigger behind ... life as miniscule larvae floating in the open ocean, ...
... Orleans, LA A team of scientists at LSU Health ... active form of E6-associated protein (E6AP), an enzyme that acts ... the first time, that the active form of E6AP is ... diverse as the ability of nerve cells to "rewire" themselves ...
... Fla. (Jan. 9, 2014) The current special issue ... National Academy of Inventors is devoted to ... Academy of Inventors (NAI) hosted by the University of ... attracted 200 inventors and innovators from 60 universities, research ...
Cached Biology News:Marine tubeworms need nudge to transition from larvae state 2LSUHSC research reveals structure of master regulator and new drug target for autism, cervical cancer 2National Academy of Inventors 2013 Conference showcased global innovation 2National Academy of Inventors 2013 Conference showcased global innovation 3National Academy of Inventors 2013 Conference showcased global innovation 4
...
Rabbit polyclonal antibody to NCOA2 [Agarose Immobilized]...
... low background ,This solution greatly enhances antigen-antibody ... than obtained with conventional methods. ,Two kinds ... secondary antibodies, which can suppress the background ... Wide versatility ,It is applicable to various ...
Mouse Anti-Human Killer Cell Immunoglobulin-like Receptor, Two Domains, Long Cytoplasmic Tail, 2 (KIR2DL2 (KIR2DL3 Monoclonal Antibody Family: Immunoglobulin Sub-Family: not assigned-Immunogl...
Biology Products: